XML 85 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated income statements - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Statement [line items]      
Net sales to third parties from continuing operations $ 48,659 $ 47,445 $ 44,751
Sales to discontinued segment   53 82
Net sales from continuing operations 48,659 47,498 44,833
Other revenues 1,239 1,179 1,266
Cost of goods sold (15,121) (14,425) (14,510)
Gross profit from continuing operations 34,777 34,252 31,589
Selling, general and administration (14,197) (14,369) (13,717)
Research and development (8,980) (9,402) (8,489)
Other income 1,742 2,031 1,629
Other expense (3,190) (3,426) (2,609)
Operating income from continuing operations 10,152 9,086 8,403
Income from associated companies 673 659 6,438
Interest expense (869) (850) (932)
Other financial income and expense (78) 45 186
Income before taxes from continuing operations 9,878 8,940 14,095
Taxes (1,807) (1,793) (1,295)
Net income from continuing operations 8,071 7,147 12,800
Net income/loss from discontinued operations before gain on distribution   (101) (186)
Gain on distribution of Alcon Inc. to Novartis AG shareholders   4,691  
Net income/loss from discontinued operations   4,590 (186)
Net income 8,071 11,737 12,614
Attributable to      
Shareholders of Novartis AG 8,072 11,732 12,611
Non-controlling interests $ (1) $ 5 $ 3
Basic earnings per share [abstract]      
Basic earnings per share, Continuing operations $ 3.55 $ 3.12 $ 5.52
Basic earnings per share, Discontinued operations   2.00 (0.08)
Basic earnings per share 3.55 5.12 5.44
Diluted earnings per share [abstract]      
Diluted earnings per share, Continuing operations 3.52 3.08 5.46
Diluted earnings per share, Discontinued operations   1.98 (0.08)
Diluted earnings per share $ 3.52 $ 5.06 $ 5.38